Latest Press Releases
- Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing
- Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis
- Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections
- Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference
- FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections
- PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients
- Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections
- Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine
- Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing